KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) Operating Margin: 2020-2023

Historic Operating Margin for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -719.61%.

  • AbCellera Biologics' Operating Margin fell 54427.00% to -719.61% in Q4 2023 from the same period last year, while for Dec 2023 it was -623.80%, marking a year-over-year decrease of 66840.00%. This contributed to the annual value of -1,091.69% for FY2024, which is 46787.00% down from last year.
  • Per AbCellera Biologics' latest filing, its Operating Margin stood at -719.61% for Q4 2023, which was up 13.49% from -831.79% recorded in Q3 2023.
  • Over the past 5 years, AbCellera Biologics' Operating Margin peaked at 77.97% during Q1 2021, and registered a low of -831.79% during Q3 2023.
  • For the 3-year period, AbCellera Biologics' Operating Margin averaged around -256.58%, with its median value being -100.39% (2021).
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 54,731bps in 2022, then crashed by 86,901bps in 2023.
  • Over the past 4 years, AbCellera Biologics' Operating Margin (Quarterly) stood at 77.33% in 2020, then plummeted by 1,880bps to 58.53% in 2021, then tumbled by 23,388bps to -175.34% in 2022, then slumped by 54,427bps to -719.61% in 2023.
  • Its Operating Margin stands at -719.61% for Q4 2023, versus -831.79% for Q3 2023 and -511.03% for Q2 2023.